McKesson Corp. has launched a new business called InspiroGene, which focuses on the commercialization of cell and gene therapies (CGTs).

InspiroGene aims to support manufacturers, payers, and providers in navigating the complex commercialization landscape of CGTs.

The new brand is designed to provide scalable and flexible services throughout the entire CGT life cycle.

InspiroGene utilizes McKesson’s extensive supply chain network to provide specialty distribution services, ensuring efficient delivery of CGTs to patients.

The business also includes biologics specialty pharmacy solutions for CGTs, featuring precise dispensing and tailored patient management services.

InspiroGene features a dedicated patient hub that offers customized access and support for patients, along with operational case management for caregivers.

InspiroGene offers specialized third-party logistics (3PL) programs that cater to the unique needs of CGT manufacturers, including financial management, logistics, and data analytics.

These logistics programs encompass financial management, advanced data analytics, and seamless operations specifically for CGTs.

Joe DePinto, head of Cell, Gene, and Advanced Therapies at McKesson, emphasized the company's commitment to transforming patient care and advancing health outcomes.

McKesson partners with various stakeholders, including biopharma companies and healthcare providers, to improve the accessibility and affordability of quality care.

InspiroGene's technology platform integrates product data and financial flows to enhance visibility and empower stakeholders in the CGT value chain.

Overall, InspiroGene addresses challenges in the CGT market with a comprehensive suite of solutions tailored for manufacturers and patients alike.